Peptide · Fact sheet

Ziconotide

Also known as Prialt · SNX-111

Ziconotide is FDA approved as Prialt for severe chronic pain in people who need intrathecal therapy and cannot tolerate or do not respond to other treatment. It is not a routine pain supplement and has a boxed warning for severe psychiatric and neurologic effects.

FDA approved for specific usesStrong human evidence for approved uses

What is Ziconotide?

Ziconotide is a synthetic version of a 25-amino-acid conopeptide originally identified in cone-snail venom.

It blocks N-type calcium channels involved in pain signaling and is delivered into the fluid around the spinal cord through specialist equipment.

Benefits & claims

It shows that a venom-derived peptide can become a non-opioid medicine for otherwise difficult pain.

Its narrow delivery setting and serious central nervous system effects are as important as its novel mechanism.

What the evidence supports

  • Controlled trials found greater average pain reduction than placebo in selected people with severe refractory pain.
  • It is not an opioid and does not work through opioid receptors, which makes its mechanism clinically distinctive.
Research areas
  • Severe chronic noncancer pain
  • Cancer- and AIDS-related pain
  • Non-opioid spinal pain signaling
  • Other highly selected pain settings under specialist research

Dosage & frequency

Product-specific label information

Prialt is a continuously infused intrathecal specialist pain medicine. Its dose cannot be transferred to intravenous or subcutaneous administration.

Prialt

Patients with severe chronic pain warranting intrathecal therapy who cannot use or do not respond adequately to other treatments

Amount
Start at no more than 2.4 mcg/day; maximum 19.2 mcg/day
Frequency
Continuous specialist infusion
Route studied or labeled
Intrathecal

Individual specialist titration; psychiatric and neurologic boxed warning.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Delivery uses an intrathecal device; it is not a general injectable pain peptide.

Interactions & precautions

  • Other CNS depressants can increase neurologic adverse effects; the label carries a boxed warning for severe psychiatric and neurologic reactions.

What is still unresolved

  • Response and tolerability require specialist titration; a plasma half-life is not an analgesic-duration estimate.

Side effects & risks

  • The boxed warning describes severe psychiatric symptoms and neurologic impairment; people with a history of psychosis should not receive Prialt.
  • Confusion, hallucinations, mood or consciousness changes, dizziness, gait problems, memory impairment, nausea, and other neurologic effects can occur.
  • Intrathecal equipment introduces risks such as meningitis and catheter or pump complications.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Strong human evidence for approved uses

Randomized placebo-controlled trials support analgesic benefit in selected severe-pain populations. Adverse effects and the need for specialist intrathecal delivery sharply limit generalization.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Mood: reported experiences

Negative account · personal report

Anxiety and depression disrupted work

A former Prialt user described worsening anxiety and depression, including a leave of absence from work, despite previously controlled mental-health symptoms.

Reported use in this account

Product
Prialt
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Pain pump; specific route not restated
Duration
Not specified clearly

Medication changes and clinical history are self-reported; this is not a verified assessment of causation.

Read the original account
Mixed account · personal report

Long-term pain relief with one early adverse experience

Another commenter described more than eight years of useful pain relief, one adverse experience during a dose increase and later pump removal after spinal stabilization.

Reported use in this account

Product
Prialt
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Pain pump; specific route not restated
Duration
More than eight years

Other exposures described: Prior long-term opioid treatment

This retrospective account followed prior opioid treatment and later spinal stabilization. It does not predict another patient's response.

Read the original account

Approval status

Prialt is FDA approved for severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatment.

Approved uses

  • Management of severe chronic pain when intrathecal therapy is warranted and other treatment is ineffective or not tolerated

FDA approved for severe chronic pain by a specific route

Ziconotide is approved under the Prialt label for intrathecal treatment of severe chronic pain in a narrow clinical context, not as a general pain remedy.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Which patients can obtain durable benefit without unacceptable neurologic effects
  • Long-term comparative outcomes versus other specialist pain approaches
  • How trial averages translate across different causes of severe pain

Summary

Prialt is approved for a specialist severe-pain setting, with serious psychiatric, neurologic and device-related risks.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA prescribing information: Prialt

    Official indication, boxed warning, safety information, and clinical-study summary.

  2. pubmedRandomized trial in severe chronic pain

    Placebo-controlled study of analgesic benefit and neurologic adverse effects.

  3. pubmedRandomized trial in chronic nonmalignant pain

    Controlled trial illustrating both pain reduction and substantial adverse effects with faster escalation.

  4. nihPrialt current prescribing information

    Primary source for the practical reference information.

How we assess sources · Suggest a correction